Beyond Borders: A Backpacker’s Take on Why Your Patent Strategy Needs a Global Mindset

​
September 29, 2025

A well-planned global patent strategy can protect your innovations, maximise commercial value, and reduce costly surprises down the line. Yet, amid the big-picture planning, it's often the small details—the formalities—that make or break your protection. It's a bit like discovering a typo in your name on a visa application just as you're about to cross into a new country: a minor oversight can quickly become a major obstacle. These procedural requirements may seem minor, but overlooking them can derail filings, delay grants, or even result in lost rights. This article explores why these formalities matter and how to manage them effectively in a global context.

Stage 1: From Invention to Initial Filing—Know Your Inventors

Before initiating any patent filing, it is essential to pause and consider your inventors—not just their technical contributions, but their citizenship and residency. You should also consider where your invention was devised. These factors can significantly influence your filing strategy and, if overlooked, may lead to serious complications.

Evaluating this information is extremely important when considering where to file your application first, whether a foreign filing license should be required, and if so, from which patent office. Getting this wrong could cause any application subsequently filed in a jurisdiction whose foreign filing rules were not complied with to be held invalid.

In most cases, patent applicants have flexibility in choosing where to file first. However, when an invention's origin intersects with national legislation, that flexibility can vanish. You may even find yourself compelled to file in a jurisdiction that holds no commercial interest, simply to comply with local law.

Let's illustrate this with the example of Greece. Under Greek law, if an invention involves a Greek national as an inventor, the first patent application must be filed in Greece—regardless of where the invention was made or the nationality of the applicant. This isn't a procedural preference; it is a legal obligation. Failing to comply could invalidate subsequent foreign filings and even trigger criminal sanctions.

Several other countries also have their own restrictions, and a helpful summary is available via the WIPO website. If there's any uncertainty, seeking advice from a locally qualified representative is strongly recommended to ensure your filing strategy aligns with all relevant national laws.

This is why a global mindset is not just beneficial—it is essential. Understanding the legal landscape across jurisdictions helps avoid missteps that could derail your patent strategy before it begins. A simple check of inventor nationality and residency should be standard practice when preparing any first filing.

Getting the first filing right is only the beginning. Much like an experienced globe-trotter double-checking their travel documents before crossing a border, the next critical step is to confirm you have all the right ownership paperwork in place before venturing further on your patent journey.


Stage 2: Bulletproof Your Ownership—Don't Assume It's Automatic

Securing patent rights isn't just about filing the application—it's about ensuring you actually own what you're trying to protect. While many businesses assume that inventions created by employees automatically belong to the employer, this is not universally true. Ownership rules vary significantly between jurisdictions, and relying on assumptions can leave dangerous gaps in your portfolio.

In some countries, rights transfer to the employer under statute, by virtue of employment, provided the invention was made in the course of what the inventor, as employee, is paid to invent by their employer. In others, explicit written agreements are required to assign rights from the inventor to the company. Even where statutory provisions exist, they may not cover every scenario—such as contractors, consultants, or employees working outside their home jurisdiction. For instance, a British inventor seconded to Japan might be considered an employee under UK law, where rights default to the employer, but still retain initial ownership under Japanese law unless clear contractual assignment and compensation provisions are in place.

Failing to address these points early can lead to disputes, delays, or even loss of rights. For example, if an inventor refuses to sign an assignment after filing, you may find yourself unable to enforce the patent in certain countries and/or sell the patent. In India, for instance, the patent office will not proceed with examination until clear ownership is established through a written assignment from the inventor to the employer. It is worth noting that these rules are not set in stone. Just as a backpacker must keep up to date with the latest entry requirements to avoid being turned away at the border, it is essential to regularly review and update your IP agreements and processes to ensure your patent rights remain secure and enforceable wherever your innovation journey takes you. Laws and practices evolve, and what is sufficient in one jurisdiction today may change tomorrow.

The safest approach? Check your agreements before you file. Ensure employment contracts and consultancy agreements include robust IP clauses that take into account the laws of all relevant jurisdictions. Where necessary, execute separate assignment documents at the time of filing. This proactive step can save you from costly headaches later and keep your global strategy watertight.

With your essentials secured, it's time to plan your route. A seasoned traveller knows that choosing the right path—whether it is a direct flight or a scenic detour—can save time, money, and a lot of unnecessary hassle.

Stage 3: Filing Strategy—Centralise Where You Can

When it comes to expanding your protection beyond the country of first filing, the route you choose can make a big difference in cost, timing, and complexity, notably with regards to formalities. For many applicants, the Patent Cooperation Treaty (PCT) offers a smart solution. It allows you to file a single international application and defer filings in individual countries (such as China) or regions (such as the European Patent Office) for up to at least 30 months from the date you filed your initial patent application.

The PCT route also helps centralise certain formalities. For example, if there's a change in ownership or inventorship, you can record it with the World Intellectual Property Organization (WIPO)—the United Nations agency that administers the PCT—during the international phase. This avoids having to repeat the process in every national office—provided those offices recognise changes recorded with WIPO. This approach can be both more efficient and more cost-effective, reducing legal fees, translation costs, and the risk of inconsistent records across jurisdictions.

Even the best-planned itinerary can unravel if you lose track of your tickets or miss a connection. Likewise, as your patent portfolio grows, keeping every detail organised is what keeps your journey on track. From signatures and notarisation requirements to tracking deadlines and coordinating local agents, the administrative load can quickly become overwhelming—especially for large portfolios.

Stage 4: Portfolio Expansion—Master the Formalities

As your portfolio grows, so does the complexity of keeping every detail of the formal requirements (formalities) aligned. Each jurisdiction has its own rules, forms, and timelines—and the differences can be subtle but critical. Missing a signature, using the wrong form, or overlooking a local notarisation requirement can derail an application or even result in lost rights. Add to that the challenge of tracking annuity deadlines, coordinating national phase entries, and ensuring ownership and inventorship records remain consistent, and the administrative burden quickly multiplies.

This is where experienced, detail-oriented paralegals prove invaluable. They not only manage internal processes but also act as the hub between multiple local agents, gathering the necessary documents, signatures, and confirmations to keep everything on track. Their ability to coordinate across jurisdictions ensures that local requirements are met efficiently and accurately.

When your backpack starts to fill up, every extra item counts. Staying organised and making smart choices about what to carry can make the difference between a smooth trip and an exhausting trek. When formalities are managed proactively, organisations not only reduce the risk of lost rights or costly errors, but also gain the ability to respond quickly to market opportunities and allocate resources more effectively. In this way, efficient portfolio management becomes a genuine competitive advantage, helping businesses protect their innovations when and where they need to, enabling them to operate with confidence, and stay ahead in a fast-moving global landscape.

From Cost Challenges to Strategic Solutions: EIP's Role in Global Patent Strategy Success

Building and maintaining a global patent portfolio is a significant investment, with costs arising from filings, translations, agent fees, and ongoing annuities. Yet, with careful planning and a strategic approach, many costs can be minimised. Centralised filings, careful checks to ensure alignment with local legal requirements, and coordinated assignments help prevent duplication and procedural errors, while strategic use of the PCT can defer expenses and provide valuable flexibility.

Think of our paralegals as the expert guides who know every shortcut, local custom, and hidden pitfall—making sure your journey is as smooth as possible, no matter how complex the route. Their expertise in managing intricate formalities, coordinating with local agents, and ensuring consistency across borders is vital to keeping costs down and portfolios secure. They proactively identify potential issues, manage deadlines, and facilitate smooth communication between all parties, ensuring that every detail is handled with precision.

At EIP, we combine strategic insight with hands-on expertise to help clients navigate the financial and procedural complexities of patenting all over the world. Our collaborative approach ensures your portfolio is protected and managed in a way that maximises both value and cost-effectiveness.

By Lucie Jones, Head of Client Services at EIP and seasoned backpacker

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​